Purity & Documentation Data Sheet (287 KB) SDS (393 KB) English - EN (393 KB) Franais - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Espaol - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB) Handling Instructions (2659 KB) References [1]
doi: 10.1111/dom.14725 61
Among previous GLP-1 users, 49 percent experienced nausea, 33 percent had diarrhea, and 32 percent reported stomach pain
BN is included here only for mechanistic completeness, as outlined in Chapter 1, because the current evidence base is extremely limited and does not support BN-specific clinical inference
Hims recommends consulting your insurance provider for specific cost and coverage details
For people with T2D, a phase 2 trial with mazdutide (doses 3, 4.5 and 6 mg) has shown reduction in HbA1c (up to 1.7%) and up to 7.1% WL at 20 weeks (Table 3), while early phase trials for MASH are in progress [72]